Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

LMG LLC

NPI: 1871919936 · METAIRIE, LA 70005 · Physical Medicine & Rehabilitation Physician · NPI assigned 03/13/2014

$43K
Total Medicaid Paid
25,814
Total Claims
21,080
Beneficiaries
23
Codes Billed
2018-01
First Month
2024-10
Last Month

Provider Details

Authorized OfficialROBERT, KEARNY (DIRECTOR)
NPI Enumeration Date03/13/2014

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 5,897 $5K
2019 3,452 $4K
2020 3,004 $4K
2021 4,362 $9K
2022 1,322 $3K
2023 4,667 $6K
2024 3,110 $12K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 10,326 8,478 $30K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 2,256 1,858 $4K
20610 931 656 $3K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3,565 3,086 $2K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 264 75 $1K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 927 916 $614.96
J1010 Injection, methylprednisolone acetate, 1 mg 307 200 $324.56
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 578 458 $272.35
J1040 Injection, methylprednisolone acetate, 80 mg 1,274 1,003 $130.68
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 14 14 $106.37
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 133 130 $57.35
73562 32 28 $21.56
73560 18 13 $18.42
J1885 Injection, ketorolac tromethamine, per 15 mg 23 20 $9.17
84311 754 615 $6.94
J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg 156 144 $6.00
82570 755 615 $5.15
83986 753 614 $3.56
81003 751 612 $2.24
99205 Prolong outpt/office vis 18 14 $0.00
99072 1,717 1,277 $0.00
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 249 242 $0.00
73565 13 12 $0.00